Current Report Filing (8-k)
09 August 2018 - 6:30AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): August 8, 2018
NEKTAR
THERAPEUTICS
(Exact
Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
0-24006
|
|
94-3134940
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
|
|
|
|
|
|
|
455
Mission Bay Boulevard South
San
Francisco, California 94158
(Address
of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: (415) 482-5300
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
|
Results
of Operations and Financial Condition.
|
On
August 8, 2018, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”)
announcing its financial results for the quarter ended June 30, 2018. A copy of the Press Release is furnished herewith
as Exhibit 99.1.
On
August 1, 2018, Nektar announced that it would hold a Webcast conference call on August 8, 2018 to review its financial results
for the quarter ended June 30, 2018. This conference call is accessible through a link that is posted on the home page and Investors
section of the Nektar website:
http://www.nektar.com
.
The
information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections
11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall
not be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar Therapeutics, whether
made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01
|
Financial
Statements and Exhibits.
|
SIGNATURES
Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
|
|
By:
|
/s/
Mark A. Wilson
|
|
|
Mark
A. Wilson
|
|
|
General
Counsel and Secretary
|
|
|
|
|
Date:
|
August
8, 2018
|
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Apr 2024 to May 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From May 2023 to May 2024